AC 699
Alternative Names: AC-0699; AC-699Latest Information Update: 30 May 2025
At a glance
- Originator Accutar Biotechnology
- Class Antineoplastics
- Mechanism of Action Estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 negative breast cancer
Most Recent Events
- 10 Dec 2024 Updated efficacy, pharmacodynamics and adverse events data from a phase I trial in HER2-negative-breast-cancer presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024) .
- 13 Sep 2024 Updated adverse events and pharmacokinetics data from a phase I trial in HER2-negative breast cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 13 Sep 2024 Accutar Biotechnology plans a phase Ib trial for HER2-negative breast cancer